Ieq Capital LLC Takes Position in Keros Therapeutics, Inc. $KROS

Ieq Capital LLC bought a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 55,675 shares of the company’s stock, valued at approximately $596,000.

Other large investors have also added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in Keros Therapeutics in the second quarter valued at approximately $29,898,000. Renaissance Technologies LLC grew its position in shares of Keros Therapeutics by 282.5% during the 4th quarter. Renaissance Technologies LLC now owns 591,686 shares of the company’s stock worth $12,047,000 after buying an additional 436,986 shares during the period. Canada Pension Plan Investment Board bought a new stake in shares of Keros Therapeutics in the 2nd quarter valued at $4,251,000. Caption Management LLC increased its stake in shares of Keros Therapeutics by 114.1% in the 2nd quarter. Caption Management LLC now owns 36,078 shares of the company’s stock valued at $482,000 after acquiring an additional 291,997 shares in the last quarter. Finally, Qube Research & Technologies Ltd lifted its position in shares of Keros Therapeutics by 683.7% during the 3rd quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock valued at $4,795,000 after acquiring an additional 264,445 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

Wall Street Analysts Forecast Growth

KROS has been the topic of several research analyst reports. Wells Fargo & Company cut their target price on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 4th. Wall Street Zen raised shares of Keros Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, August 24th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Keros Therapeutics in a report on Tuesday, August 4th. Leerink Partners cut their price objective on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $20.50.

Keros Therapeutics Trading Down 1.8%

Shares of KROS stock opened at $11.03 on Friday. The firm has a market capitalization of $218.72 million, a PE ratio of -2.98 and a beta of 0.99. The firm has a fifty day simple moving average of $10.78 and a two-hundred day simple moving average of $11.61. Keros Therapeutics, Inc. has a 12 month low of $9.69 and a 12 month high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. On average, equities analysts predict that Keros Therapeutics, Inc. will post -5.27 earnings per share for the current fiscal year.

Insider Buying and Selling at Keros Therapeutics

In related news, Director Julius Knowles sold 2,625 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the sale, the director owned 10,958 shares in the company, valued at $117,579.34. This represents a 19.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the transaction, the director directly owned 9,767 shares in the company, valued at approximately $104,799.91. The trade was a 21.18% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 13,768 shares of company stock valued at $144,979. Insiders own 12.60% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-?) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.